At the start of 2021, 70 companies raised the price of hundreds of prescription drugs by an average of 3.3%.
The Coalition for Healthcare Communication will present a special post-election webinar on Nov. 19 featuring Kate Rawson – senior editor of Prevision Policy and an experienced, well-connected inside-the-beltway observer – with a more in-depth look at implications of the 2020 elections for healthcare policy.
Novartis said new interim data from an ongoing phase clinical trial for the company’s $2.1 million-per-patient gene therapy Zolgensma showed spinal muscular atrophy patients experienced significant therapeutic benefit.
Over the past five years, the Institute for Clinical and Economic Review pressured drugmakers to lower the cost of nearly 100 drugs. ICER aims to play a similar role with emerging Covid-19 treatments and vaccines.
The U.S. House Oversight Committee decided to subpoena AbbVie Inc. to seek documents on the drugmaker’s blockbuster treatments, Humira and Imbruvica, as part of an investigation into drug pricing practices.
The U.S. Food and Drug Administration approved an oral treatment from Roche Holding AG and PTC Therapeutics Inc. for spinal muscular atrophy in adults and children two months and above.
Novartis’ Sandoz division will not profit from 15 generic drugs the company is making available to developing countries to treat symptoms of Covid-19 for the pandemic’s duration, the Swiss drugmaker said.
Aimmune Therapeutics Inc. said 80 percent of patients being treated with the company’s Palforzia were successfully desensitized to peanut proteins after two years of daily dosing.
With the 2020 elections looming though, and lawmakers across the country drafting legislation aimed at curbing price increases, some companies are carefully examining the landscape as they approach pricing.
Roche is expecting the U.S. Food and Drug Administration to approve the company’s SMA therapy risdiplam by May 24, 2020, and has suggested plans to undercut both Biogen and Novartis on price in order to make up for being third-to-market.
